Toxicity, Adverse Events, and Quality of Life Associated with the Treatment of Metastatic Castration-Resistant Prostate Cancer

Abstract

Objectives: Among males, prostate cancer (PCa) is the most common cancer in Europe and the second most common cancer worldwide, especially in those aged > 70 years. With the advent of novel alternative treatments, survival in patients with advanced PCa has increased. PCa is now considered a chronic disease. Survival is an important endpoint in advanced PCa, as is quality of life (QoL). The effects of the disease and its treatment on patient health-related QoL must be taken into account when selecting the most appropriate treatment options. The present literature review aimed to provide an overview of metastatic castration-resistant prostate cancer treatment modalities, with an emphasis on side effect profiles and general health-related QoL. Methods: PubMed was searched using the keywords metastatic castration-resistant prostate cancer, docetaxel, cabazitaxel, enzalutamide, abiraterone acetate, and QoL. Conclusion: Based on the studies reviewed herein, abiraterone acetate and enzalutamide provide favorable outcomes, in terms of hematological adverse events. As enzalutamide and abiraterone acetate can be taken orally, they might have a positive effect on patient QoL.

Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review

“…Markov chain models should be preferred for modelling the cost-effectiveness of mCRPC, as it is possible to model longer periods with uncertain timing of death [39, 131, 132]. Current treatment options for mCRPC have shown to prolong survival in patients, whereby the risk of adverse events related to their treatment is high [133, 134]. Consequently, decision tree models are inadequate to capture complex scenarios, as in current treatment options for mCRPC [131, 132].…”

Glucosinolate-Degradation Products as Co-Adjuvant Therapy on Prostate Cancer in Vitro

“…Recently, there is no satisfactory treatment for PC when the cancer cells lose responsiveness to ADT [12]. DOCE is a therapeutic alternative but with important side effects and limited anti-cancer response, among other aspects due to the appearance of resistance [3,4]. These disadvantages could be addressed by combination therapies.…”

“…Currently, taxane drugs such as docetaxel (DOCE), are indicated for both the treatment of recurrent hormone-sensitive PC in combination with androgen deprivation therapy (ADT) and treatment of castration-resistant prostate cancer (CRPC) [2]. However, since taxanes have limited effectiveness as well as high toxicity [3,4], there is an urgent need for new treatment strategies in order to try to solve these drawbacks.…”

“…MSR, of treated group/DMSO-treated control group. 2 p value was determined by one-way ANOVA followed by Tukey's test 3. Survival rate of DOCE group multiplied by survival rate of the PEITC group 4.…”

A comprehensive mechanistic basis of prostate cancer advancement & its personalized implementation-bridging the gap: present state and future prospect

“…In addition to these challenging aspects, there are other serious issues including toxicity burdens, severe treatment side effects like sexual dysfunction and high costing of the entire treatment procedure due to use of highly expensive treatment modalities [31][32][33][34]. For increasing efficacies and determining the optimal sequencing strategies among currently used therapeutics, there is an urgent need to get a comprehensive view over these resistance mechanisms in prostate cancer.…”